Dyania Health
2019
Year Founded
2022
Year Selected
New York, US / Athens, Greece
Location(s)
21-50
Team Size
THE MISSION
Dyania Health, a member of the Scale Up 5 Batch, was founded in 2019 and is backed by venture funding. The company has developed Synapsis AI, an advanced system that combines a tailored large language model with a physician-driven algorithm to automate the review of electronic medical records (EMRs). This technology efficiently screens both structured and unstructured patient data to identify individuals who qualify for clinical trials of innovative therapies for serious health conditions. With a strong team of full-time physicians and AI researchers, Dyania Health specializes in natural language processing and has extensive experience in clinical research, drug development, and EMR workflows. Their solutions comply with HIPAA and GDPR, ensuring quick integration across North America and Europe.
Dyania recently secured $10 million in Series A funding, led by HealthX Ventures and with support from Tech Square Ventures and Cleveland Clinic Ventures. This investment will enhance their AI capabilities and foster partnerships with leading organizations to advance clinical research and improve patient care outcomes.
Dyania in Three:
What problem is Dyania solving? Dyania Health helps healthcare providers quickly find patients who qualify for clinical trials by automating the review of electronic medical records (EMRs) with its Synapsis AI platform.
What’s innovative Dyania? The company is innovative because it combines a specially designed AI language model with a system that uses doctor-driven algorithms to analyze patient data from EMRs.
Who can use Dyania? Healthcare providers and organizations involved in clinical research can use Dyania Health's technology to improve patient recruitment for clinical trials.
OUR TAKE
Dyania Health is disrupting and transforming the way companies and research organizations leverage unstructured data that can create immense clinical value. The Dyania Health team has a combined over 800 academic publications and 120 years of experience in clinical research, drug development, and clinical technologies with backgrounds across top-tier organizations including Morgan Stanley and Amazon.